Your browser version may not work well with NCBI's Web applications. More information here...
1: Endocr Relat Cancer. 2001 Sep;8(3):237-48.Click here to read Links

Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment.

Stein RC.

The Ludwig Institute for Cancer Research and Department of Oncology, Royal Free and University College London Medical School, 91 Riding House Street, London W1W 7BS, UK. rstein@ludwig.ucl.ac.uk

The phosphoinositide 3-kinases (PI3-kinases) are a family of lipid kinases that have a key role in the regulation of many cellular processes including proliferation, survival, carbohydrate metabolism, and motility. There is now strong evidence that some members of the PI3-kinase family have an important role in cancer. Emerging evidence for functional specialisation of PI3-kinase isoforms suggests that isoform selective inhibitors, in contrast to the existing non-selective inhibitors wortmannin and LY294002, may prove to be useful anticancer drugs.

PMID: 11566615 [PubMed - indexed for MEDLINE]